Vectura Group PLC (VEC) Insider Andrew Derodra Acquires 127 Shares
Vectura Group PLC (LON:VEC) insider Andrew Derodra bought 127 shares of the firm’s stock in a transaction on Wednesday, January 17th. The shares were purchased at an average price of GBX 118 ($1.60) per share, for a total transaction of £149.86 ($203.23).
Andrew Derodra also recently made the following trade(s):
- On Friday, December 8th, Andrew Derodra bought 153 shares of Vectura Group stock. The shares were purchased at an average price of GBX 98 ($1.33) per share, for a total transaction of £149.94 ($203.34).
- On Wednesday, November 8th, Andrew Derodra acquired 156 shares of Vectura Group stock. The shares were bought at an average cost of GBX 96 ($1.30) per share, with a total value of £149.76 ($203.09).
Vectura Group PLC (LON:VEC) opened at GBX 115.40 ($1.56) on Thursday. Vectura Group PLC has a fifty-two week low of GBX 86.50 ($1.17) and a fifty-two week high of GBX 166.97 ($2.26).
ILLEGAL ACTIVITY NOTICE: This piece was first reported by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/18/vectura-group-plc-vec-insider-andrew-derodra-acquires-127-shares.html.
Vectura Group Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.